Bacterial infections have long been a major cause of serious diseases and high mortality worldwide, with the rise of drug-resistant strains further diminishing the effectiveness of antibiotics. Consequently, rapid and accurate bacterial detection has become an urgent challenge. AIE probes, known for their high brightness, large Stokes shift, strong resistance to photobleaching, and excellent biocompatibility, are promising candidates for fluorescence imaging. However, their limited targeting ability and low delivery efficiency hinder optimal therapeutic outcomes. Bacteriophages, which are highly biocompatible and can specifically target host bacteria, have been underused in clinical settings due to their relatively slow and limited efficacy, particularly in acute infections. By linking AIEgens to bacteriophages, AIE-phage bioconjugates can be formed, enhancing both specificity and efficiency in bacterial targeting, labeling, imaging, and intervention. These bioconjugates offer a simple, low-cost solution for rapid bacterial screening, especially in clinical diagnostics and food safety. Researches indicated that AIE-phage bioconjugates had significant potential in combating drug-resistant bacteria, identifying pathogens, and monitoring microbial contamination. AIE-phage bioconjugates are poised to play a critical role in advancing antibacterial research and clinical diagnostics.